Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma

Frontiers in Medicine

Zhongmin Zou¹  Kaniel Cassady²  Yimei Feng³  Xi Zhang³  Xiaoqi Wang³ 

[1] Department of Chemical Defense Medicine, School of Military Preventive Medicine, Third Military Medical University, Chongqing, China;Irell and Manella Graduate School of Biological Sciences of City of Hope, Duarte, CA, United States;Medical Center of Hematology, The Xinqiao Hospital of Third Military Medical University, Chongqing, China;

关键词: PD1;    autologous stem cell transplantation;    Hodgkin's lymphoma;    beam;    case report;   

DOI  :  10.3389/fmed.2021.693023

来源: DOAJ

【 摘 要 】

The emergence of new drugs has provided additional options in the treatment of relapsed and refractory (R/R) Hodgkin's lymphoma (HL). However, the use of autologous stem cell transplantation (ASCT) has not been completely replaced in this setting. The use of anti-programmed death-1 (PD-1) antibody bridging to ASCT and as maintenance after transplantation is a novel approach in HL treatment. In this case, we report that PD-1 monoclonal antibody (mAb) plus ASCT with modified BEAM regimen (carmustine + etoposide + cytarabine + melphalan) containing high-dose cytarabine to treat R/R HL may represent a promising regimen in this difficult-to-treat setting.

【 授权许可】

Unknown